NCT04334863: AflacST1901: Peds WP1066

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 3 Years to 25 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Patients must have previously undergone standard-of-care treatment including surgery, radiation, and/or first line adjuvant chemotherapy prior to the experimental treatment
Exclusions: Patients over the age of 25 years

Comments are closed.

Up ↑